No Data
No Data
Chongqing Zhifei Biological Products (300122.SZ): Quadrivalent recombinant norovirus vaccine enters Phase III clinical trial.
Chongqing Zhifei Biological Products (300122.SZ) announced on July 29 that the company has recently learned that the quadrivalent recombinant norovirus vaccine (Bacillus yeast) (hereinafter referred to as the "quadrivalent recombinant norovirus vaccine") developed by its wholly-owned subsidiary Anhui Zhifei Longma Biopharmaceutical Co., Ltd. has entered Phase III clinical trials in Guangxi, Hunan, and Sichuan. The quadrivalent recombinant norovirus vaccine contains the currently main prevalent strains and genotypes of norovirus and is prepared using gene engineering technology to express virus-like particles (VLPs). Norovirus is the main pathogen causing outbreaks of acute gastroenteritis in the world, affecting approximately one-fifth of the global population.
Chongqing Zhifei Biological Products (300122.SZ): As of July 19th, the number of ordinary shareholders of the company is 0.1111 million.
Chongqing Zhifei Biological Products (300122.SZ) stated on the investor interaction platform on July 26th that as of July 19th, 2024, the number of common shareholders of the company was 111,092.
Chongqing Zhifei Biological Products (300122.SZ) has seven self-developed products on the market, one of which is conditionally listed, including vaccine products for preventing meningitis, pneumonia, and other infectious diseases.
Chongqing Zhifei Biological Products (300122.SZ) stated on the investor interaction platform that the company has 7 proprietary products on the market and 1 proprietary product conditionally approved for listing, including vaccines for preventing infectious diseases such as meningitis and pneumonia, as well as drugs that provide effective solutions for the diagnosis, prevention, and treatment of tuberculosis infections. The company has a total of 31 research projects, among which the quadrivalent flu vaccine is in the stage of applying for listing, and clinical trials of freeze-dried human rabies vaccine (MRC-5 cells) and influenza virus split vaccine have been completed. Five products including the 15-valent pneumococcal conjugate vaccine and fractional pertussis vaccine are in phase III clinical trials.
Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Largest Shareholder, CEO Rensheng Jiang Sees Holdings Value Fall by 4.9% Following Recent Drop
Chongqing Zhifei Biological Products (300122.SZ): Respiratory syncytial virus (RSV) vaccine in the R&D pipeline is currently in the preclinical research stage.
On June 14, Gelonhui reported that an investor asked Chongqing Zhifei Biological Products (300122.SZ) on the investor interaction platform, "May I ask at what stage the company's RSV vaccine research and development is at?" The company replied that the respiratory syncytial virus (RSV) vaccine in its research and development pipeline is currently in the preclinical stage.
Chongqing Zhifei Biological Products is betting on a new vaccine, and wealthy investors in Chongqing have made new moves.
Planning to create a third listed company? Caixin Investor website reported that Zhifei Biological Products (stock code: 300122.SZ), a vaccine giant, has new actions from its actual controller. At the end of May this year, the company announced that the actual controller Jiang Rensheng pledged 6.895 million shares in the company for equity investments, who already has two listed companies before. This investment also makes the market curious about Jiang Rensheng's next capital layout. In the vaccine market, Zhifei Biological Products has gone from being on the brink of bankruptcy to having the highest market cap of over 300 billion yuan, reflecting not only the era but also personal business judgment. Jiang Rensheng himself has also crossed over from vaccines to innovative drugs and has successfully determined the capital investment each time.
No Data